CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
Potential Benefits
- May support increased growth hormone secretion in a physiologic pulsatile pattern
- Research suggests potential improvements in body composition
- May support recovery from exercise and injury
- Studies indicate possible improvements in sleep quality
- May support skin elasticity and collagen production over time
Recommended Starting Dose
100 mcg subcutaneously per injection
Based on published research protocols. Not a prescription.
Dosing Protocol
Commonly injected 1-3 times daily (before bed, upon waking, and/or post-workout) at 100 mcg per dose. Often combined with Ipamorelin at 100-200 mcg. Typical cycles run 8-12 weeks with a 4-week break. Best administered on an empty stomach.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Sleep improvements may be noticed within the first 1-2 weeks. Body composition and recovery changes typically emerge over 6-12 weeks of consistent use.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Flushing and warmth at injection site
- Headache
- Dizziness
- Potential water retention
- Transient numbness or tingling in extremities
- May affect blood sugar regulation
More in Growth Hormone
CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is a long-acting GHRH analog that includes a Drug Affinity Complex, which binds to albumin in the blood and extends its half-life to approximately 6-8 days. This results in sustained elevation of growth hormone levels rather than pulsatile release. It was developed by ConjuChem Biotechnologies.
Ipamorelin
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is considered one of the milder GH secretagogues, producing a targeted GH pulse without significant increases in cortisol, prolactin, or appetite. It is frequently combined with CJC-1295 (no DAC).
Sermorelin
Sermorelin Acetate
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the naturally occurring 44-amino-acid GHRH molecule. It was previously FDA-approved for diagnosing and treating growth hormone deficiency in children. It stimulates the pituitary to produce and release GH in a natural, pulsatile manner.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.